These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28350139)

  • 41. miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
    Liu K; Liu S; Zhang W; Ji B; Wang Y; Liu Y
    Int J Oncol; 2014 Oct; 45(4):1537-46. PubMed ID: 25096647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
    Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
    Savić R; He X; Fiel I; Schuchman EH
    PLoS One; 2013; 8(5):e65620. PubMed ID: 23724146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.
    Kishikawa T; Otsuka M; Tan PS; Ohno M; Sun X; Yoshikawa T; Shibata C; Takata A; Kojima K; Takehana K; Ohishi M; Ota S; Noyama T; Kondo Y; Sato M; Soga T; Hoshida Y; Koike K
    Oncotarget; 2015 Apr; 6(10):8339-52. PubMed ID: 25826076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.
    Jang JY; Jeon YK; Lee CE; Kim CW
    Int J Oncol; 2013 Feb; 42(2):574-82. PubMed ID: 23242177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
    Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
    Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
    Nam SW; Park KC; Yang KJ; Lee B; Kim SW
    Int J Oncol; 2014 Oct; 45(4):1450-6. PubMed ID: 25017961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
    Luo L; Cai L; Luo L; Tang Z; Meng X
    Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
    Lin YT; Chao CC
    Oncotarget; 2015 Nov; 6(36):38999-9017. PubMed ID: 26517516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
    Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Yoon EL; Yeon JE; Ko E; Lee HJ; Je JH; Yoo YJ; Kang SH; Suh SJ; Kim JH; Seo YS; Yim HJ; Byun KS
    J Korean Med Sci; 2017 Feb; 32(2):212-220. PubMed ID: 28049231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Xia H; Ooi LL; Hui KM
    Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
    Kim JB; Lee M; Park SY; Lee S; Kim HR; Lee HS; Yoon JH; Kim YJ
    Mol Med Rep; 2015 Dec; 12(6):8247-52. PubMed ID: 26460271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
    Abeni E; Salvi A; Marchina E; Traversa M; Arici B; De Petro G
    Int J Oncol; 2017 Jul; 51(1):128-144. PubMed ID: 28560380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.
    Nam SW; Park KC; Choi HS; Lee B; Kim SW
    J Gastroenterol Hepatol; 2014 Mar; 29(3):633-9. PubMed ID: 24716227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
    Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
    J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.